5-氟尿嘧啶联合重组人细胞珠蛋白治疗缺氧诱导化疗耐受肝细胞癌的体外实验

In vitro study of 5⁃FU combined with rhCYGB in treating hypoxia⁃induced chemotherapy resistance of hepatocellular carcinoma

目的探讨联合使用重组人细胞珠蛋白(rhCYGB)靶向缺氧诱导的5-氟尿嘧啶(5-FU)治疗耐受在肝癌中的作用及机制。以期为改善难治性肝癌提供一种新的联合治疗策略。方法在常氧和缺氧条件下检测不同药物对肝癌细胞的半数抑制率并绘制量效曲线,评估不同氧浓度下肝癌细胞对5-FU的敏感性。使用CompuSyn和SynergyFinder 3.0软件分析不同浓度rhCYGB和5-FU在常氧和缺氧条件下处理肝癌细胞的联合效应。肿瘤干细胞成球实验评估联合用药对肝癌干细胞性的作用。流式细胞术检测联合用药对CD133阳性细胞亚群比例的影响。划痕实验评估联合用药对肝癌细胞迁移的影响。结果缺氧条件下5-FU处理Hep3B、Huh7和HepG2细胞IC50值显著高于常氧条件下IC50值(P<0.05),分别为常氧条件下的15.27、4.25、2.34倍。常氧和缺氧条件下5-FU联合rhCYGB具有协同效应。与5-FU单药组相比,5-FU联合rhCYGB对肝癌干细胞球的形成具有抑制作用(P<0.05),且可显著下调Hep3B细胞中CD133阳性亚群比例(P<0.05)。常氧条件下rhCYGB联合5-FU处理48 h后对Hep3B细胞的迁移具有联合抑制作用(P<0.05)。结论rhCYGB与5-FU联合运用在肝癌中具有协同效应;联合机制可能涉及干细胞性及细胞迁移能力的调控。

Objective This study explores the efficacy and underlying mechanisms of combining rhCYGB with 5-FU to target hypoxia-induced treatment resistance in liver cancer.The aim is to develop a novel combinato‐rial therapy strategy for improving outcomes in patients with refractory liver cancer.Methods The half-maximal inhibitory concentration(IC50)of drugs on liver cancer cells under normoxia and hypoxia was determined,and dose-response curves were generated to assess sensitivity to 5-FU.The combined effects of rhCYGB and 5-FU were analyzed withCompuSyn and SynergyFinder 3.0.Tumor stem cell sphere formation assays and flow cytometry for CD133-positive cells were conducted to evaluate the impact on cancer stemness.Wound healing assays assessed the effects on migration.Results The IC50 values under hypoxia exhibited a significant fold change compared to normoxia(P<0.05),specifically a 15.27-fold,4.25-fold,and 2.34-fold increase for Hep3B,Huh7,and HepG2 cells respectively.Assessment of drug combination effects demonstrated a synergistic interaction between 5-FU and rhCYGB.Compared to the 5-FU monotherapy group,the combination of 5-FU and rhCYGB exerted an inhibitory effect on the formation of liver cancer stem cell spheres(P<0.05)and significantly downregulated the proportion of CD133-positive subpopulations in Hep3B cells(P<0.05).Wound healing assay results revealed a synergistic inhibitory effect on the migration of Hep3B cells after 48 hours of treatment with rhCYGB combined with 5-FU undernormoxia(P<0.05).Conclusions The combination of rhCYGB and 5-FU demonstrates syner‐gistic effects in liver cancer.The underlying mechanism may involve the modulation of stemness and cell migration capacity.